Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454621 | 1.00 | RAB9A (0.35) | RAB9APOLBDPP4GRM5DGAT2 | |
| SCHEMBL456434 | 0.84 | DGAT2 (0.38) | RAB9APOLBDGAT2TP53ROCK2 | |
| SCHEMBL15436223 | 0.82 | RAB9A (0.35) | RAB9APOLBDPP4MAPTNPC1 | |
| SCHEMBL456081 | 0.81 | LMNA (0.35) | RAB9ADPP4GRM5DGAT2MAPT | |
| SCHEMBL456080 | 0.81 | LMNA (0.35) | RAB9ADPP4GRM5DGAT2MAPT | |
| SCHEMBL15436224 | 0.71 | DHODH (0.35) | RAB9APOLBDPP4DGAT2NPC1 | |
| SCHEMBL452218 | 0.69 | RAB9A (0.39) | RAB9APOLBDGAT2TP53ROCK2 | |
| SCHEMBL454487 | 0.66 | RAB9A (0.45) | RAB9APOLBMAPTNPC1GCGR | |
| SCHEMBL453626 | 0.66 | ABL1 (0.44) | DGAT2TP53ROCK2 | |
| SCHEMBL2260453 | 0.64 | CTSA (0.47) | DGAT2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | RAB9A 3699/4885POLB 4302/4885DPP4 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.